Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure. Results From the A-HeFT Trial

Journal of the American College of Cardiology

Volumn 48, Issue 6, 2006, Pages 1277-1282

  McNamara, Dennis M ^a   Tam, S William ^b   Sabolinski, Michael L ^b   Tobelmann, Page ^a   Janosko, Karen ^a   Taylor, Anne L ^c   Cohn, Jay N ^c   Feldman, Arthur M ^d   Worcel, Manuel ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NitroMed Inc   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ALDOSTERONE SYNTHASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; ISOSORBIDE;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CYP11B2 GENE; ENZYME ACTIVITY; EVALUATION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

AFRICAN AMERICANS; AGED; ALDOSTERONE SYNTHASE; ALLELES; CARDIAC OUTPUT, LOW; COHORT STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HOSPITALIZATION; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 33748428075     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.07.030     Document Type: Article

References (36)

1. White P.C. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab 88 (2003) 2376-2383
2. Pitt B., Zannad F., Remme W.J., et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
3. Pitt B., Remme W., Zannad F., et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
4. Bassett M.H., White P.C., and Rainey W.E. The regulation of aldosterone synthase expression. Mol Cell Endocrinol 217 (2004) 67-74
5. White P.C., Hautanen A., and Kupari M. Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function. J Steroid Biochem Mol Biol 69 (1999) 409-412
6. White P.C., and Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 21 (1995) 437-442
7. Brand E., Chatelain N., Mulatero P., et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 32 (1998) 198-204
8. White P.C., and Rainey W.E. Polymorphisms in CYP11B genes and 11-hydroxylase activity. (editorial). J Clin Endocrinol Metab 90 (2005) 1252-1255
9. Connell J.M.C., Fraser R., MacKenzie S.M., et al. The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation. Mol Cell Endocrinol 217 (2004) 243-247
10. Lim P.O., MacDonald T.M., Holloway C., et al. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J Clin Endocrinol Metab 87 (2002) 4398-4402
11. Tsukada K., Ishimitsu T., Teranishi M., et al. Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. J Hum Hypertens 16 (2002) 789-793
12. Kumar N.N., Benjafield A.V., Lin R.C., et al. Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension. J Hypertens 21 (2003) 1249-1253
13. Patel S., Steeds R., Channer K., et al. Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarction. Am J Hypertens 13 (2000) 134-139
14. Hautanen A., Toivanen P., Manttari M., et al. Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation 100 (1999) 2213-2218
15. Yancy C.W. Heart failure in African Americans. Am J Cardiol 96 (2005) 3i-12i
16. Taylor J.S., and Ellis G.R. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure. Am J Cardiovasc Drugs 2 (2002) 389-399
17. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
18. McNamara D.M., Holubkov R., Postava L., et al. Phamacogenetic interactions between ACE inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 44 (2004) 2019-2026
19. Taylor A.L. The African-American Heart Failure Trial (A-HeFT): rationale and methodology. J Card Fail 9 Suppl 5 (2003) S216-S219
20. Pojoga L., Gautier S., Blanc H., et al. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 11 (1998) 856-860
21. Barbato A., Russo P., Siani A., et al. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J Hypertens 22 (2004) 1895-1901
22. Paillard F., Chansel D., Brand E., et al. Genotype-phenotype relationships for the renin-aldosterone system in a normal population. Hypertension 34 (1999) 423-429
23. Kathiresan S., Larson M.G., Benjamin E.J., et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham heart study. Am J Hypertens 18 (2005) 657-665
24. Zhu H., Sagnella G.A., Dong Y., et al. Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. J Hypertens 21 (2003) 87-95
25. Price D., and Fisher N.D. The renin-angiotensin system in blacks: active, passive of what?. Curr Hypertens Rep 5 (2003) 225-230
26. Preston R.A., Matersn B.J., Reda D.J., et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 280 (1998) 1168-1172
27. Henderson S.O., Haiman C.A., and Mack W. Multiple polymorphisms in the renin-angiotensin-aldosterone system (ACE, CYP11B2, AGTR1) and their contribution to hypertension in African Americans and Latinos in the multiethnic cohort. Am J Med Sci 328 (2004) 266-273
28. Flack J.M., Oparil S., Pratt J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41 (2003) 1148-1155
29. Ben-Yehuda O. Hypertension, angiotensin II, aldosterone and race. J Am Coll Cardiol 41 (2003) 1156-1158
30. Kupari M., Hautanen A., Lankinen L., et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 97 (1998) 569-575
31. Mayosi B.M., Keavney B., Watkins H., et al. Measured haplotype analysis of the aldosterone synthase gene and heart size. Eur J Hum Genet 11 (2003) 395-401
32. Ergul A. Hypertension in black patients. An emerging role of the endothelial system in salt sensitive hypertension. Hypertension 36 (2000) 62-67
33. 173Arg and -334T/C variants of CYP11B2 in Japanese patients with low-renin hypertension. Hypertension 35 (2000) 699-703
34. Duffy S.J., Biegelsen E.S., Eberhardt R.T., et al. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 46 (2005) 707-713
35. Sanz-Rosa D., Oubina M.P., Cediel E., et al. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signal 7 (2005) 1294-1301
36. Carson P., Ziesche S., Johnson G., Cohn J.N., and Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 5 (1999) 178-187